How should we pay for gene therapy?
By Aaron Carroll (The Incidental Economist),
Academy Health Blog
| 05. 27. 2016
For many, many years we’ve been hearing about gene therapy – the chance that we can get into people’s DNA and fix it to resolve problems and fix disease. In a recent piece in Science, Stuart Orkin and Philip Reilly discuss what finally achieving success might mean:
Imagine a young man with hemophilia A who no longer has to self-administer factor VIII replacement; an individual with sickle cell disease who is free of chronic pain and intermittent crises; a girl functionally blind since the age of 5 who can now see; or a baby rescued from a fatal, inherited neurodegenerative disease. For decades, gene therapy has tantalized us with such futuristic scenarios. However, these goals are now coming into focus, and it is the time to consider some of the consequences of success.
As they report, gene therapy has been forty-four years in the making. But gene therapy, which has cost billions of dollars in research and development, is different from the traditional pharmaceutical market. For one thing, most diseases which are the focus of gene therapy research are relatively...
Related Articles
By Meagan Parrish, PharmaVoice | 10.10.2025
When CEO Ben Lamm steps into the spotlight, it’s usually to talk about his efforts bringing extinct animals back to life. Once a far-flung idea, Lamm and the company he heads, Colossal Biosciences, have proven they can pull it off...
By Jessica Mouzo, El País | 10.03.2025
DNA is the molecule of life: this double-helix structure, present in every cell in the body and organized into fragments called genes, stores the instructions for making organisms function. It is a highly precise biological machine, but sometimes it breaks...
By Katherine Bourzac, Nature | 09.25.2025
A judge in New York rejected a request on 23 September to disqualify the use of cutting-edge DNA sequencing as evidence in a case against an alleged serial killer. The ruling paves the way for a type of DNA analysis...
By Claire Robinson, GMWatch | 09.29.2025
According to an article on BBC News, the Quadram Institute in Norwich is recruiting 76 people with low vitamin D to take part in the ViTaL-D Study, where some participants will eat soup containing tomatoes that have been genetically...